Immunologic and Targeted Molecular Therapies for Chordomas: A Narrative Review
Authors:
- Regina GoldingRGRegina Golding
- Rami AbuquboRARami Abuqubo
- Christopher J. PansaCPChristopher J. Pansa
- Manish BhattaMBManish Bhatta
- Vishal ShankarVSVishal Shankar
- Kyle ManiKMKyle Mani
- Emily KleinbartEKEmily Kleinbart
- Yaroslav GelfandYGYaroslav Gelfand
- Saikiran MurthySMSaikiran Murthy
- Rafael De la Garza RamosRRRafael De la Garza Ramos
- Jonathan KrystalJKJonathan Krystal
- Ananth EleswarapuAEAnanth Eleswarapu
Open Access
- 24 September 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (19) , 5679
Abstract
Chordomas are rare sarcomas arising from notochordal tissue and occur most commonly in the spine. The standard of care for chordomas without evidence of metastatic disease generally consists of en bloc resection followed by adjuvant radiotherapy. However, long-term (20-year) survival rates are approximately 30%. Chordomas are generally considered as chemo resistant. Therefore, systemic therapies have rarely been employed. Novel immunotherapies, including antibody therapy and tumor vaccines, have shown promise in early trials, leading to extended progression-free survival and symptom relief. However, the outcomes of larger trials using these vectors are heterogeneous. The aim of this review is to summarize novel chordoma treatments in immune-targeted therapies. The current merits, trial outcomes, and toxicities of these novel immune and targeted therapies, including those targeting vascular endothelial growth factor receptor (VEGFR) targets and the epidermal growth factor receptor (EGFR), will be discussed.Keywords
This publication has 54 references indexed in Scilit:
- RETRACTED ARTICLE: Proton beam therapy for skull base chordomas: a systematic review of tumor control rates and survival ratesNeurosurgical Review, 2022
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal TherapyTargeted Oncology, 2021
- Surgical Management of Skull Base and Spine ChordomasCurrent Treatment Options in Oncology, 2021
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable ChordomaThe Oncologist, 2021
- Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic valueEuropean Spine Journal, 2020
- Descriptive epidemiology of chordomas in the United StatesJournal of Neuro-Oncology, 2020
- Low dose radiotherapy is associated with local complications but not disease control in sacral chordomaJournal of Surgical Oncology, 2019
- Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical studyCancer, 2018
- Role of iron in the enhancement byAgrobacterium tumefaciens infection in miceFolia Microbiologica, 1988
- Chordoma: Natural history and treatment results in 33 casesJournal of Surgical Oncology, 1988